Abstract: The invention relates to a device and method for preparing a structure or object using an additive manufacturing process referred to as sequential cold spray laser sintering. The method includes depositing by cold spraying a plurality of sequential layers of material onto a substrate/build plate or particles of materials onto a compacted powder bed of material and employing an energy source to sinter or melt each of the plurality of sequential layers or powders to produce sequential sintered layers, wherein the number of additional layers is determined based on those needed to produce the final structure.

Abstract: Disclosed herein are methods and systems for transient-based decoding of neural signals. In one aspect, a device such as a brain-computer interface (BCI), includes at least one processor configured to receive a plurality of neural signals from a subject. The at least one processor can detect, from the plurality of neural signals, first neural activity unique to a first defined temporal window corresponding to an onset phase of an intended action of the subject. The at least one processor can detect, from the plurality of neural signals, second neural activity unique to a second defined temporal window, occurring after the first temporal window and corresponding to an offset phase of the intended action. The at least one processor can generate at least one output indicative of the intended action, responsive to detecting at least one of the first neural activity or the second neural activity.

Abstract: Methods are disclosed for treating an acute respiratory distress syndrome, such as an acute respiratory distress syndrome associated with a viral infection, such as SARS-CoV2 (COVID-19) in a subject in need thereof. These methods include administering to the subject a pharmaceutical preparation comprising isolated matrix bound vesicles (MBV) derived from extracellular matrix.

Abstract: A multi-lumen implantable device configured to deliver a therapeutic agent to a selected portion of a blood vessel is disclosed. As one example, an implantable device includes a first lumen configured to flow blood from an upstream end to a downstream end of the device when implanted in a blood vessel; a second lumen fluidly separated from the first lumen and configured for introducing a therapeutic agent to a selected, first portion of a wall of the blood vessel, between the upstream end and the downstream end of the device; and at least one sealing member configured to block the therapeutic agent from entering a second portion of the wall of the blood vessel, between the upstream end and the downstream end of the device.

Abstract: Methods are disclosed for polarizing macrophages to become M2 macrophages. Methods also are disclosed for treating type 1 diabetes in a subject. These methods include administering to the subject a vector comprising a macrophage specific promoter operably linked to a nucleic acid molecule encoding TNF-alpha-induced protein 8-like 2 (TIPE2) protein. In some embodiments, the vector is administered locally to a pancreas of the subject. In further embodiments, compositions are disclosed including a) a vector comprising a macrophage specific promoter operably linked to a nucleic acid molecule encoding TNF-alpha-induced protein 8-like 2 (TIPE2) protein; b) a buffer; and c) a contrast dye for endoscopic retrograde cholangiopancreatography.

Abstract: Peptides capable of enhancing N-methyl D-aspartate (NMDA) receptor activity by inhibiting binding of the NMDA receptor GluN2A to zinc transporter 1 (Zn1) are described. The GluN2A-derived peptides can be used to in the treatment of disorders associated with NMDA receptor hypofunction, such as schizophrenia.

Abstract: The invention relates to luminescence-based compounds, compositions and methods for chemical sensing in solid state and solutions. More particularly, the invention includes “turn-on” lanthanide sensors that luminesce only in the presence of an organic compound (analyte) and are non-emissive in the absence of the organic compound (analyte).

Abstract: The present invention relates to oncolytic vaccinia viruses which have been modified to promote anti-tumor immunity and/or reduce host immunity and/or antibody response against the virus. It is based, at least in part, on the discovery that oncolytic vaccinia virus (i) bearing a genome deletion of a gene that reduces T cell immunity (interleukin-18 binding protein); (ii) treated with a sialidase enzyme which is believed to reduce TLR2 activation and therefore the antibody response; (iii) carrying a gene that enhances cytotoxic T lymphocyte induction (e.g., TRIF) and/or (iv) reduces tumor myeloid-derived suppressor cells by reducing prostaglandin E2 reduces tumor growth. Accordingly, the present invention provides for immunooncolytic vaccinia viruses and methods of using them in the treatment of cancers.

Abstract: Disclosed herein are methods of treating a subject with an estrogen receptor-positive (ER+) breast cancer comprising obtaining a sample of the breast cancer from the subject; determining a level of E-cadherin in the sample is reduced compared to a control; and administering a therapeutically effective amount of an IGF1R pathway inhibitor and an endocrine therapeutic. Also disclosed herein are methods to treat a cancer in a subject comprising administering a therapeutically effective amount of an IGF1R pathway inhibitor and an E-cadherin inhibitor. Also disclosed are methods to predict the likelihood a subject with a breast cancer will respond therapeutically to a treatment comprising administering an IGF1R pathway inhibitor, the method comprising obtaining a sample of the cancer from the subject; and determining a level of E-cadherin in the sample.

Abstract: Compositions for treating an ocular disorder are provided. The composition includes an effective amount of a human trabecular meshwork stem cell (TMSC) secretome, wherein the effective amount is present in an amount to reduce impairment of retinal ganglion cells (RGC). Methods for treating ocular disorders using the disclosed compositions are also provided. The compositions reduce and prevent cell apoptosis, axon loss, vision loss, increased intraocular pressure, and dysregulated aqueous humor outflow of a subject when used in accordance with the methods disclosed herein.

Abstract: Methods for treating an ear condition in a subject, comprising topically administering to the ear of the subject in need thereof a composition comprising: (i) an anti-infective agent-loaded biodegradable polymer microspheres; and (ii) a thermoresponsive hydrogel.

Abstract: The invention relates to complex framework materials (CFMs) for lithium-sulfur batteries. The CFMs include a CFM host and a coating applied to the CFM host, which includes one or more of an electronic conductor, a lithium ion conductor and a functional catalyst. Further, sulfur is infiltrated into the CFM host creating a sulfur-carbon linkage serving as effective anchors for trapping polysulfides. The systems have been tested in coin cells and pouch cells under lean electrolyte conditions of 3-4 ?l/mg of electrolyte to sulfur ratios showing promise and feasibility.

Abstract: A method for quantifying an amount of fat contained in a liver or other tissue of a subject in vivo includes varying the temperature of a target area in a subject, imaging thermal strain of the target area using an ultrasound scanner, and quantifying the amount of fat in the targeted area based on the thermal strain imaging. In some embodiments, the thermal strain imaging is performed using high-resolution, phase-sensitive speckle tracking to differentiate between fat-based tissue and water-based tissue.

Abstract: The present invention relates to systems and methods for the treatment of conditions of chronic inflammation, such as periodontitis, that includes the use of sustained release microparticles to locally deliver a compound or agent to reduce inflammation of tissue, such as periodontal tissue, and/or inflammatory mediators.

Abstract: Disclosed are compositions and methods for the detection of a Flavivirus infection. In some embodiments, the method comprises detecting a recent Flavivirus infection by measuring the amount of anti-NS1 IgG3. In other embodiments, the method comprises detecting a prior Dengue virus infection in a subject previously immunized with a Dengue virus vaccine comprising one or more non-Dengue Flavivirus proteins.

Abstract: The present invention relates to an ovarian-derived hydrogel material, which can be useful for three-dimensional in vitro culturing of cells, cell therapy, fertility preservation, drug delivery, site-specific remodeling and repair of damaged tissue, and/or diagnostic kits.

Abstract: A compound of formula I, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof: wherein X1 is benzimidazolyl, substituted benzimidazolyl, azabenzimidazolyl, substituted azabenzimidazolyl, pyrazolyl, or substituted pyrazolyl; X2 is aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, cycloalkyl, substituted cycloalkyl, (cycloalkyl)alkyl, substituted (cycloalkyl)alkyl, heterocycloalkyl, substituted heterocycloalkyl, (heterocycloalkyl)alkyl, substituted (heterocycloalkyl)alkyl, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, dialkylaminocarbonyl, substituted dialkylaminocarbonyl, (heterocycloalkyl)carbonyl, or substituted (heterocycloalkyl)carbonyl; X3 is alkyl, substituted alkyl, alkenyl, substituted alkenyl, heterocycloalkyl, substituted heterocycloalkyl, (heterocycloalkyl)alkyl, substituted (heterocycloalkyl)alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heter

Abstract: A gas sensor (100,200) includes at least one sensor device including a surface acoustic wave (SAW) device (110) or a quartz crystal microbalance (QCM) device (210), and a layer of metal organic framework (MOF) material (120,220) disposed on each of the at least one sensor device. The at least one sensor device is structured to sense a change in mass of the MOF material.

Abstract: The inventive concepts include at least an electrode architecture including a composite structure that includes engineered carbon nanofibers, a lithium-impervious elastic polymer, a copper collector and a lithium-containing cathode; dendrite-free, lithium metal-plated anode that includes the electrode architecture; and a lithium metal-based lithium ion battery that includes the lithium metal-plated anode, liquid and solid electrolytes and a lithium-free cathode.

Abstract: An optically transparent actuator apparatus is provided that includes an optically transparent bi-stable member including an optically transparent liquid crystalline polymer layer. The bi-stable member is structured to move from a first state to a second state in response to a first stimulus and from the second state to the first state in response to a second stimulus. Also, a display apparatus includes a plate member and an actuator assembly coupled to the plate member. The actuator assembly includes a number of optically transparent liquid crystalline polymer layers, wherein each of the optically transparent liquid crystalline polymer layers is structured to move from a first state to a second state in response to a first stimulus.